Диссертация (1139554), страница 51
Текст из файла (страница 51)
// Вестник РОНЦ им. Н.Н. БлохинаРАМН. 2008. Т.19, №3, стр.16-25.86. Чикилева И.О., Шубина И.Ж., Киселевский М.В. Влияние регуляторных Т-клеток на функциональную активность натуральных киллеров при иммунотерапии злокачественных опухолей. // Вестник РАМН. 2012. №4, стр.60-64.87. Шатрова А.Н., Зенин В.В., Аксенов Н.Д., Митюшова Е.В., Марахова И.И. Поверхностная экспрессия СD25 у лимфоцитов человека на разных стадиях запуска пролиферативного ответа. Действие интерлейкина-2. // Цитология. 2011.Т.53, №8, стр.652-658.88. Шевцов М.А., Маргулис Б.А., Хачатрян В.А. Иммунотерапия в клиническойонкологии: новые парадигмы в создании противораковых вакцин.
// Нейрохирургия и неврология детского возраста. 2012. №4(34), стр.94-102.89. Шубина И.Ж., Чикилева И.О., Михайлова И.Н., Демидов Л.В., ОгородниковаЕ.В., Тазаев В.Н., Киселевский М.В. Активированные натуральные киллеры вклеточной иммунотерапии. // Российский иммунологический журнал. 2012.Т.6, №1(15), стр.71-79.90. Яковлев В.Н., Зыков Д.В., Рябинская Г.В., Цуркан В.А., Логинов С.П., Алексеев В.Г., Шехоян А.С., Царев М.И. Способ лечения больных раком легкого.RU 2500435. 10.12.2013.91. Ярилин А.А., Донецкова А.Д. Естественные регуляторные Т-клетки и факторfoxp3. // Иммунология.
2006. Т.27, №3, стр.176-188.92. Abramova V.A., Kali A., Abdolla N. et al. Influence of tumor cells on natural killercell phenotype and cytotoxicity. // International Journal of Biology and Chemistry 8.2015; 1(9): 9-14.93. Anfossi N., André P., Guia S. et al. Human NK cell education by inhibitory receptorsfor MHC class I. // Immunity. 2006; 25: 331-342.94. Anokhin Yu.N. Nano-technologies and nano-materials for cancer imaging and therapy. // Advances in current natural sciences.
2014; №5 (part 2): 14-25.95. Arreygue-Garcia N.A., Daneri-Navarro A., del Toro-Arreola A. et al. Augmentedserum level of major histocompatibility complex class I-related chain A (MICA) pro-268tein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. // BMC Cancer. 2008; 8: 16.96. Bachanova V., Burns L.J., McKenna D.H. et al. Allogeneic natural killer cells forrefractory lymphoma. // Cancer Immunol Immunother. 2010; 59(11): 1739-1744.97. Bachanova V., Miller J.S. NK cells in therapy of cancer. // Critical Reviews in Oncogenesis.
2014; 19(1-2): 133-141.98. Bacher N., Raker V., Hofmann C. et al. Interferon-α suppresses cAMP to disarm human regulatory T cells. // Cancer Research. 2013; 73: 5647-5656.99. Bae D.S., Hwang Y.K., Lee J.K. Importance of NKG2D NKG2D ligands interactionfor cytolytic activity of natural killer cell. // Cell. Immunol. 2012; 276: 122-127.100. Bahram S.
MIC genes: from genetics to biology. // Adv Immunol. 2000; 76: 1-60.101. Balandin T.G., Edelweiss E., Andronova N.V. et al. Antitumor activity and toxicityof anti- HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts. // Invest. New Drugs. 2009; 29(1): 22–32.102. Bauer S., Groh V., Wu J., Steinle A. et al.
Activation of NK cells and T cells byNKG2D, a receptor for stress-inducible MICA. // Science. 1999; 285: 727-729.103. Baychelier F., Sennepin A., Ermonval M. et al. Identification of a cellular ligand forthe natural cytotoxicity receptor NKp44. // Blood. 2013; 122: 2935-2942.104. Becknell B., Caligiuri M.A. Interleukin-2, interleukin-15, and their roles in humannatural killer cells. // Advances in Immunology. 2005; 86: 209-239.105.
Belicha-Villanueva A., Riddell J., Naveen B., Gollnick S.O. The effect of photodynamic therapy on tumor cell expression of Major Histocompatibility Complex(MHC) Class I and MHC Class I-related. // Mol Lasers Surg Med. 2012; 44, 1: 6068.106. Belldegrun A., Uppenkamp I., Rosenberg S.A. Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renalcell cancer. // Urology. 1988; 139(1): 150-155.107.
Bellora F., Castriconi R., Dondero A. et al. The interaction of human natural killercells with either unpolarized or polarized macrophages results in different functionaloutcomes. // PNAS. 2010; 107(50):21641-21659.108. Berdeja J.G., Hess A., Lucas D.M. et al. Systemic interleukin-2 and adoptive transfer269of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-Cell lymphoma treated with rituximab. // ClinicalCancer Research.
2007; 13: 2392-2399.109. Biassoni R. Human natural killer receptors, co-receptors, and their ligands. CurrentProtocols in Immunology. 2009; Chapter 14, Unit 14.10.110. Biron C.A., Byron K.S., Sullivan J.L. Severe herpesvirus infections in an adolescentwithout natural killer cells. // New Eng J of Medicine. 1989; 320:1731-1735.111. Björkström N.K., Riese P., Heuts F. et al. Expression patterns of NKG2A, KIR, andCD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-celleducation. // Blood. 2010; 116(19): 3853-3864.112.
Bonavida B. NK cell phenotypic and functional heterogeneities and molecular mechanisms of cytotoxicity. // Critical Reviews in Oncogenesis. 2014; 19(1-2): 21-45.113. Bottino C., Castriconi R., Moretta L., Moretta A. Cellular ligands of activating NKreceptors. // Trends in Immunology. 2005; 26: 221.114.
Brandt C.S., Baratin M., Yi E.C. et al. The B7 family member B7-H6 is a tumor cellligand for the activating natural killer cell receptor NKp30 in humans. // ExperimentalMedicine. 2009; 206(7):1495-1503.115. Bryceson Y.T., Fauriat C., Nunes J.M. et al. Functional analysis of human NK cellsby flow cytometry. // Methods in Molecular Biology. 2010; 612: 335-352.116. Burgess S.J., Maasho K., Masilamani M. et al. The NKG2D receptor: immunobiology and clinical implications.
// Immunologic Research. 2008; 40: 18-34.117. Burnet F.M. The concept of immunological surveillance. // Progress in experimentaltumor research. 1970; 13: 1-27.118. Burns L.J., Weisdorf D.J., DeFor T.E. et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation andcytokine release: a phase I/II trial. // Bone Marrow Transpl. 2003; 32: 177-186.119.
Caligiuri M. Human natural killer cells. // Blood. 2008; 112(3): 461-469.120. Campbell M.J., Tonlaar N.Y., Garwood E.R., et al. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinicaloutcome. // Breast Cancer Research and Treatment.
2011; 128: 703-711.270121. Cancer Biology в книге Cancer Medicine. 6th ed. Kufe D.W.; Pollock R.E.; Weichselbaum R.R.; Bast R.C., Jr.; Gansler T.S.; Holland J.F.; Frei III, Emil, editors. Hamilton (Canada): BC Decker Inc; 2003122. Capece D., Fischietti M., Verzella D. et al. The inflammatory microenvironment inhepatocellular carcinoma: a pivotal role for tumor-associated macrophages. // BioMed Research International. 2013; 187204.123. Carbone E., Neri P., Mesuraca M., et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.
//Blood. 2005; 105: 251-258.124. Carson W.E., Ross M.E., Baiocchi R.A. et al. Endogenous production of interleukin15 by activated human monocytes is critical for optimal production of interferongamma by natural killer cells in vitro. // Clinical Investigation. 1995; 96: 2578-2582.125. Castriconi R., Dondero A., Bellora F., Moretta L. et al. Neuroblastoma-derived TGFbeta1 modulates the chemokine receptor repertoire of human resting NK cells. // Immunology. 2013; 190: 5321-5328.126.
Cerwenka A., Bakker A.B., McClanahan T. et al. Retinoic acid early inducible genesdefine a ligand family for the activating NKG2D receptor in mice. // Immunity. 2000;12: 721-717.127. Chan A., Hong D.L., Atzberger A. et al. CD56bright human NK cells differentiateinto CD56dim cells: role of contact with peripheral fibroblasts. // Immunology. 2007;179: 89-94.128.
Chan H.W., Kurago Z.B., Stewart C.A. et al. DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. // Experimental Medicine.2003; 197: 245-255.129. Chan H.W., Miller J.S., Moore M.B., Lutz C.T. Epigenetic control of highly homologous killer Ig-like receptor gene alleles. // Immunology.
2005; 175: 5966-5974.130. Chang Y.T., Wu C.C., Shyr Y.M. et al. Secretomebased identification of ULBP2 asa novel serum marker for pancreatic cancer detection. // PLoS One. 2011; 6(5):e20029.131. Chen D., Gyllensten U. MICA polymorphism: biology and importance in cancer. //Carcinogenesis. 2014; 35(12): 2633-2642.271132. Chen X.M., Xu X.Q., Sun K. et al. NKG2D ligands expression and NKG2Dmediatedcytotoxicity in human laryngeal squamous carcinoma cells.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
